[{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Gameday Men\u2019s Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Gameday Men\u2019s Health","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Gameday Men\u2019s Health"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Numan","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Numan","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Numan"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Duke University School of Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Duke University School of Medicine"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"USSM","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Partnership","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ USSM","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ USSM"},{"orgOrder":0,"company":"Marius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Marius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Marius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marius Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Marius Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The partnership aims to explore the potential of Kyzatrex (testosterone undecanoate) in improving patient outcomes before and after surgery, critical care, and acute or chronic illness.

                          Product Name : Kyzatrex

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          March 03, 2025

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Duke University School of Medicine

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The partnership aims to distribution of KYZATREX (testosterone undecanoate), an FDA approved. It is used to treat adult men who have low or no testosterone levels due to certain medical conditions.

                          Product Name : Kyzatrex

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          January 14, 2025

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : USSM

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Marius partners with Numan to commercialize Kyzatrex (testosterone undecanoate) capsules for the treatment of patients suffering from deficiency or absence of endogenous testosterone.

                          Product Name : Kyzatrex

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          September 18, 2024

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Numan

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Kyzatrex (testosterone undecanoate) is an oral formulation absorbed via the lymphatic system, not toxic to the liver, indicated for adult males with testosterone deficiency conditions.

                          Product Name : KYZATREX

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          September 01, 2024

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Kyzatrex (testosterone undecanoate) is an oral testosterone replacement therapy designed to treat adult men with low or no testosterone levels due to certain medical conditions.

                          Product Name : Kyzatrex

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          July 30, 2024

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The deal gives Gameday Men’s Health patients access to the FDA-approved oral testosterone therapy, Kyzatrex, indicated in adult males for deficiency or absence of endogenous testosterone.

                          Product Name : Kyzatrex

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          March 12, 2024

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Gameday Men’s Health

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          07

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : KYZATREX™ (testosterone undecanoate) is a proprietary softgel oral formulation absorbed primarily via the lymphatic system (meaning it is not toxic to the liver) indicated in adult males for conditions associated with a deficiency or absence of endogen...

                          Product Name : Kyzatrex

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          September 18, 2023

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : KYZATREX™ (testosterone undecanoate) is a proprietary softgel oral formulation absorbed primarily via the lymphatic system (meaning it is not toxic to the liver) indicated in adult males for conditions associated with a deficiency or absence of endogen...

                          Product Name : Kyzatrex

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          September 21, 2022

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : KYZATREX™ is an oral testosterone replacement therapy ("TRT") indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.

                          Product Name : Kyzatrex

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          February 08, 2022

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : KYZATREX®, an oral testosterone undecanoate softgel, had one of the most comprehensive Phase 3 trials in the testosterone space and if approved, has the potential to be the only first-action approval oral testosterone product on the market.

                          Product Name : Kyzatrex

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          November 03, 2021

                          Lead Product(s) : Testosterone Undecanoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank